Treatment of acquired transthyretin amyloidosis in domino liver transplantation.

Konstantinos Ioannis TsamisDimitrios MytilinaiosMichael HeneghanJulian D GillmoreJanet A GilbertsonSotirios GiannopoulosIoannis SarmasSpyridon Konitsiotis

Published in: Clinical transplantation (2022)

The case presented here supports the concept that patisiran can target the hepatocytes producing the mutated transthyretin in acquired transthyretin amyloidosis, as efficiently as in hereditary transthyretin amyloidosis (hATTR), and can be used to treat patients with transthyretin amyloidosis after DLT.

Keyphrases

wild type
multiple myeloma
liver injury
replacement therapy
drug induced